Lv2
130 积分 2025-10-20 加入
TIM-3 Inhibitor Development: Overcoming Immune Evasion in Cancer Therapy
4天前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
1个月前
已完结
Delivery of Peptide-LYTAC via Polyporus Polysaccharide Microneedles for Targeted CD47 Degradation and Enhanced Tumor Immunotherapy
2个月前
已完结
Degrader-Drug Conjugate (DDC) Mediated Immunochemotherapy for Tumor Treatment
2个月前
已完结
Development of Integrin-Facilitated Bispecific Aptamer Chimeras for Membrane Protein Degradation
4个月前
已完结
A Bivalent Aptamer-Based DNA Agonist for EGFR Signaling Effectively Alleviates Ulcerative Colitis In Vivo
4个月前
已完结
Abstract P6-10-02: MHC-II positive breast tumors are more immunogenic and may preferentially select for LAG-3-positive tumor immune infiltrates
4个月前
已关闭
Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy
4个月前
已完结
皖公网安备34019202002308
